By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A new company called Oxford Cancer Biomarkers has been formed to provide oncology consulting services and new cancer biomarkers.

The company, which is headquartered in Oxford and Reading, UK, is developing new biomarkers using CancerNav, a DNA- and protein-based assay technology platform developed by Nick La Thangue, chair of cancer biology at Oxford University, and David Kerr, professor of cancer medicine at the university.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At her blog, Sally Rockey dives into National Institutes of Health funding data.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.